Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033657 | 0.85 | HTT (0.50) | HTTCNR2POLBLMNACNR1 | |
| SCHEMBL6123494 | 0.81 | HTT (0.45) | HTTPOLBLMNAKDM4EALDH1A1 | |
| SCHEMBL637498 | 0.81 | HTT (0.45) | HTTPOLBLMNAKDM4EALDH1A1 | |
| SCHEMBL715894 | 0.79 | — | — | |
| SCHEMBL11350868 | 0.78 | HTT (0.40) | HTTCNR2POLBLMNAKDM4E | |
| SCHEMBL19052251 | 0.74 | — | — | |
| SCHEMBL4827396 | 0.73 | GAA (0.43) | POLBKDM4EALDH1A1CYP3A4GAA | |
| SCHEMBL10545379 | 0.73 | MEN1 (0.40) | POLBKDM4EALDH1A1GAA | |
| SCHEMBL29107984 | 0.72 | CA2 (0.41) | HTTLMNAKDM4EALDH1A1TP53 | |
| SCHEMBL4612423 | 0.71 | HTT (0.77) | HTTCNR2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100400039-C | Composition for treating tumor diseases and application thereof | BURZYNSKI STANISLAW R (US) | 2008-07-09 | — | — | CN | disclosed |
| CN-1660061-A | Composition for treating tumor diseases and application thereof | BURZYNSKI STANISLAW R (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1605334-A | Use of composition in preparing medicine for treating tumor diseases | BURZYNSKI STANISLAW R (US) | 2005-04-13 | — | — | CN | disclosed |
| CN-1191064-C | Pharmaceutical composition containing phenylacetylglutamine, phenylacetylisoglutamine and/or derivatives thereof | BURZYNSKI STANISLAW R (US) | 2005-03-02 | — | — | CN | disclosed |
| CN-1090970-C | Process for preparing uropoly acid-peptide composition | YONGSHENG PHARMACEUTICAL CO LT (CN) | 2002-09-18 | — | — | CN | disclosed |
| CN-1090971-C | Uropoly acid-peptide composition | YONGSHENG PHARMACEUTICAL CO LT (CN) | 2002-09-18 | — | — | CN | disclosed |
| CN-1088597-C | Uropoly aic-peptide composition and its usage | YONGSHENG PHARMACEUTICAL CO LT (CN) | 2002-08-07 | — | — | CN | disclosed |
| CN-1319010-A | Therapeutic methods for administering phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | BURZYNSKI STANISLAW R (US) | 2001-10-24 | — | — | CN | disclosed |
| CN-1293959-A | Uropoly aic-peptide composition and its usage | YONGSHENG PHARMACEUTICAL CO LT (CN) | 2001-05-09 | — | — | CN | disclosed |
| CN-1294000-A | Process for preparing uropoly acid-peptide composition | YONGSHENG PHAMACEUTICAL CO LTD (CN) | 2001-05-09 | — | — | CN | disclosed |
| CN-1294001-A | Uropoly acid-peptide composition | YONGSHENG PHARMACEUTICAL CO LT (CN) | 2001-05-09 | — | — | CN | disclosed |